Registration

 Please take a few minutes to sign in using the link or QR Code below. The QR Code can be scanned with your phone's camera to open the link.

http://sgiz.mobi/s3/Jan-GP



DISCLOSURES

This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea

Cardea Services is approved as a provider of continuing nursing education by Montana Nurses Association, an accredited approver with distinction by the American Nurses Credentialing Center's Commission on Accreditation.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Institute for Medical Quality/California Medical Association (IMQ/CMA) through the joint providership of Cardea and Northwest Portland Area Indian Health Board. Cardea is accredited by the IMQ/CMA to provide continuing medical education for physicians.

Cardea designates this live web-based training for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim credit commensurate with the extent of their participation in the activity.





DISCLOSURES

COMPLETING THIS ACTIVITY

Upon successful completion of this activity 1 contact hour will be awarded Successful completion of this continuing education activity includes the following:

- Attending the entire CE activity;
- Completing the online evaluation;
- Submitting an online CE request.

Your certificate will be sent via email If you have any questions about this CE activity, contact Michelle Daugherty at <u>mdaugherty@cardeaservices.org</u> or (206) 447-9538



CONFLICT OF INTEREST

Dr. Jorge Mera is director of a program partially funded by Gilead and received an honorarium from ABBVIE.

None of the other planners or presenters of this CE activity have any relevant financial relationships with any commercial entities pertaining to this activity.



Acknowledgement

This presentation is funded in part by:

The Indian Health Service HIV Program and The Secretary's Minority AIDS Initiative Fund



Hepatitis C Virus Elimination

Jorge Mera, MD, FACP



Outline

- Why is HCV elimination needed in AI/AN communities
- Overview of HCV elimination
- Micro elimination?
- Overview of the Cherokee Nation Health Services HCV elimination program (or Micro-elimination?)
- Impact of the program and conclusions

AI/AN: American Indian/Alaskan Natives

In the USA, 68% of Acute Cases of HCV Report IDU



Source: CDC, National Notifiable Diseases Surveillance System (NNDSS) Photograph courtesy of Jorge Mera, MD, permission to reproduce consented IDU: Injection Drug Use

Change in HCV Incidence is Associated with Increases in Injection Drug Use



~31,000 new HCV infections in 2015
1:1 male: female ratio, predominantly white
Highest incidence- 20-29 years, non-urban areas



Suryaprasad, CID 2014, Zibbell MMWR 2015, CDC unpublished data

Figure 4.4. Incidence of acute hepatitis C, by race/ethnicity — United States, 2001–2016





Source: CDC, National Notifiable Diseases Surveillance System (NNDSS)

Feasibility Criteria for Elimination

In General ¹	Hepatitis C Virus	Check list
No non- human reservoir and the organism can not multiply in the environment	No non human reservoir	\checkmark
There are simple and accurate diagnostic tools	Serology widely available	
Practical interventions to interrupt transmission	Treatment as prevention Needle and syringe programs Medication assisted programs	
The infection can in most cases be cleared from the host	Treatment is 95% curative	

Adapted from Hopkins D. Disease Eradication. N Engl J Med 2013;368:54-63

Linkage to Care

HCV

Screening

THE CHEROKEE TRAIL OF TEARS

The forced removal of more than 15,000 Cherokee from the eastern U.S. to Oklahoma resulted in the deaths of thousands. Fort Armistead, near Coker Creek in Monroe County, was used as a collection point along the historic Unicoi Turnpike.

duction gies

Quality of Care

Prevent



*Maria Yellow Horse Bra Journal of Psychoactive I

HCV Elimination: Definitions and Goals

<u>Definition</u>:

- Elimination of hepatitis C as a *public health problem*

• <u>Goals</u>:

- National Viral Hepatitis Action Plan 2017-2020¹

- Decrease in new infections by 60 % by the year 2020
- Decrease in mortality by 25 % by the year 2020

- National Academy of Sciences²

- Decrease the incidence of new infections by 90% by the year 2030
- Decrease in mortality by 65 % by the year 2030

1. <u>https://www.cdc.gov/hepatitis/hhs-actionplan.htm</u> 2. National Academies of Sciences, Engineering, and Medicine. 2017. *A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report.* Washington, DC: The National Academies Press

Key Concepts to Guide HCV Elimination

Decrease the burden of HCV related liver diseases by treating the chronically infected population

- Birth cohort (patients born between 1945-1965/1975*)
- > Anyone infected for 20 + years or with multiple liver comorbidities

Decrease new infections by preventing transmission

- > Mainly target the younger population who are PWID
 - Treatment as prevention /MAT/Needle and syringe programs
- Address unsafe medical practices
- Address sexual transmission in MSM

Edlin BR, Winkelstein ER. 2014. Antiviral Research. 110:79-93 Grebely J, Dore GJ. 2014. Antiviral Research. 104:62-72 *Shah H, Bilodeau M, et al. CMAJ June 04, 2018 190 (22) E677-E687 PWID: People Who Inject Drugs MAT: Medication Assisted Treatment MSM: Men who have Sex with Men

What is HCV Micro Elimination?

- Rapidly tackling HCV in a well defined population
 - People who inject drugs
 - People with hemophilia
 - People who are incarcerated
 - People who are HIV/HCV co-infected
 - People from a defined health system
 - People in hemodialysis units, etc.etc.etc.
- Focusing elimination efforts in smaller affected populations allows for quick, efficient targeting of treatment and prevention services
- Micro-elimination strategies can help build momentum where logistic and political challenges hamper national plans for elimination

Cherokee Nation



- Sovereign Nation within a Nation
- One of the 566 Federally recognized tribes and 2nd largest Indian Nation (~350,000 citizens)
- Tripartite government
- 14 county area (over 9,200 sq mi.)
- Capitol located in Tahlequah, Oklahoma
- Largest Tribal Health System in the USA

- One central hospital and 8 outlying clinics
- Medically serves 130,000 AI/AN
- Unified electronic health record.
- 80,928 unique patients ages 20-69 visit the health system in a 3 year period

Goal #1: Secure Political Commitment

HCV Awareness Day October 31, 2015





"As Native people and as Cherokee Nation citizens, we must keep striving to eliminate hepatitis C from our population." Chief Bill John Baker

Goal #2: HCV Screening Expansion

Universal Screening

• Ages 20-69

Non-Traditional Screening Sites

- Emergency Department
- Urgent Care
- Dental Clinics
- OBGYN

Screening Modalities

- EHR Reminders
- Point of care antibody test
- Lab Triggered screening

Cost-effectiveness: HCV Testing Expansion

- "In addition to risk-based testing, one time HCV testing of persons 18 and older appears to be cost-effective, leads to improved clinical outcomes and identifies more persons with HCV than the current birth cohort recommendations. These findings could be considered for future recommendation revisions".
 - Barocas JA et al. Population-level Outcomes and Cost Effectiveness of Expanding the Recommendation for Age-based
 Hepatitis C Testing in the United States Clinical Infectious Diseases,
 Volume 67, Issue 4, 1 August 2018, Pages 549–556

Goal #2: HCV Screening Expansion Interventions and Outcomes

<u>Period</u>	<u>Interventions</u>	<u>Number of Unique</u> <u>Patients Screened</u> <u>(% seropositive)</u>	<u>Number of</u> <u>Patients</u> <u>Screened</u> per month	<u>% HCV</u> <u>Seropositive Patients</u> <u>Born after 1965</u>
1/2006 - 9/2012	 High Risk Patients Patients with cirrhosis Patients with elevated LFT's 	5,425 (10.8%)	57	?

Goal #3: Link to Care, Treat, and Cure

Before HCV Evaluation			
Patient Navigator	During Evaluation		
 Medication Procurement Specialist Public Health Nurse Link the patient to the clinic for appointment with HCV Provider Initial point of contact between the clinic and the patient 	Licensed Drug and Alcohol Counselor • If substance use disorder is present, appropriate referrals are made (MAT, Counseling, Psychiatry, etc.) Utilize ECHO for Primary Care providers	After Treatment Initiation Clinical Case Manager Pharmacist Community Health Worker • Follow the patient during treatment to help ensure adherence and follow up to SVR • Sometimes will include direct observed therapy (DOT)	
Goals			
Link to care Treat 85% 85%	Cure 85%	Cherokee Nation Health Servi	ces, 2018

The CNHS Comprehensive HCV Care Model

CNHS HCV Clinical Capacity Expansion 1/2014 – 6/2018

*Providers included 1 Specialist, 8 Physicians, 8 Pharmacists and 7 Nurse Practitioners Cure rates did not differ by provider type

Cherokee Nation Health Services, 2018

Goal #4: Reduce the incidence of new HCV infections

MAT: Medication assisted treatment NSP: Needle and syringe program

Cherokee Nation Health Services, 2018

Syringe Service Programs (SSP) and Medication Assisted Treatment (MAT) Prevent HCV Transmission

SSP and MAT effective in reducing self-reported injecting risk behaviour
 Limited evidence for effect on HCV transmission^{1,2}

New Cochrane systematic review³

MAT alone decreases risk by 50%

SSP alone decreases risk by 56% (in Europe)

MAT + SSP jointly decreases risk by 71%

		Risk	%
Reference		Ratio (95% CI)	Weight
High NSP coverage			
Hope, 2011		0.17 (0.02, 1.54)	4.85
Bruneau, 2015	÷.	0.63 (0.37, 1.07)	20.26
Van Den Berg, 2007	-	0.15 (0.06, 0.40)	13.66
Palmateer, 2014	-	0.24 (0.10, 0.60)	14.81
Subtotal (I-squared = 64.4%, p = 0.038)	\diamond	0.29 (0.13	, 0.65
Low NSP coverage			
Hope, 2011	÷	- 1.08 (0.31, 3.82)	10.54
Van Den Berg, 2007	÷	1.04 (0.53, 2.05)	18.03
Palmateer, 2014	÷.	0.48 (0.24, 0.95)	17.85
Subtotal (I-squared = 29.6%, p = 0.242)	0	0.76 (0.44, 1.33)	46.42
Overall (I-squared = 62.2%, p = 0.014)	\diamond	0.47 (0.27, 0.80)	100.00
	analysis		

1 Palmateer , Addiction 2010, 2 Hagan, JID 2011, 3 Platt Cochrane Database Syst Rev. 2016;2016(1)

CNHS HCV Cascade of Care 2012

Cherokee Nation Health Services, 2018

CNHS HCV Cascade of Care 2017

Cherokee Nation Health Services, 2018

Conclusions

- Elimination of HCV is possible by the year 2030
- Effective interventions are available
- If logistic, political or "other" challenges are present
 HCV Micro-elimination can be the answer
- Priority issues must be addressed to meet elimination goals
- Planning and commitment can accelerate the process
- The CNHS HCV elimination program is based on
 - Universal Screening
 - Robust primary care work force (projectECHO)
 - Harm reduction interventionsTreatment as prevention/Medication assisted therapy

Registration

 If you haven't already done so, please take a few minutes to sign in using the link or QR Code below. The QR Code can be scanned with your phone's camera to open the link.

http://sgiz.mobi/s3/Jan-GP

